Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria
about
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniaeBeta-lactamase inhibitors from laboratory to clinicThree decades of beta-lactamase inhibitorsbeta-Lactamases in laboratory and clinical resistanceTigemonam, an oral monobactamStructural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosaPenetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosaEvaluation of aztreonam in experimental bacterial meningitis and cerebritis.Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunctionSME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains.Distribution of [14C]aztreonam in rat tissueSingle-dose pharmacokinetics of aztreonam in pediatric patientsEvaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-upMultiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United StatesIn vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate.Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2.Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogsInteraction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteriaDiscovery and development of new antimicrobial agents.Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines.Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa.Novel genetic environment of the plasmid-mediated KPC-3 gene detected in Escherichia coli and Citrobacter freundii isolates from China.Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis.SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients.TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamasesImipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.Antibacterial activity of BMS-180680, a new catechol-containing monobactam.In vitro antibacterial activity and interactions with beta-lactamases and penicillin-binding proteins of the new monocarbam antibiotic U-78608.Profiling of β-lactam selectivity for penicillin-binding proteins in Escherichia coli strain DC2.In vitro evaluation of tigemonam, a novel oral monobactam.In vitro activities of aztreonam, imipenem, and amoxycillin-clavulanate against ampicillin-resistant Haemophilus influenzaeAztreonam treatment of gram-negative septicemiaIn vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.Antibacterial activity of Ro 17-2301 and other antimicrobial agents against cefotaxime-resistant aerobic gram-negative bacilli.Aztreonam concentration in abdominal tissues and bile.Aztreonam in the treatment of severe urinary tract infections in pediatric patients.
P2860
Q24550605-E173B668-106B-4665-9473-083E92AD8556Q24617277-3BBA416D-2199-4CC1-A0CA-3BBCC6B6318FQ24646623-2626B0F9-EDEB-46DE-BCD0-938CF25E321FQ24669605-7B298903-C6B4-4944-92D0-FC88A4A05A96Q24674177-232BC73F-D4D0-40CF-85E0-BAD28431364EQ27666204-A78D210B-6EE1-4F7E-A369-A45D60F659E2Q30451285-5338F26C-EE17-4907-AA85-9136173CBDEBQ30451337-F81ADCCE-70AE-40F6-A1BE-63628791CFF2Q30451345-2214B003-A52A-4926-8959-9A952F03EA62Q33594111-CB8191D4-E253-454A-9FE4-06C492AB8FD6Q33736772-F85AB481-6657-4B5C-8D1E-8A1C7B315C60Q33737281-158C50B6-A256-4D29-84B9-F9B0D92C0F59Q33737588-F62A3517-9750-4B62-A49F-938BE6A806FAQ33752745-5F7EF8E3-5262-4623-9FDE-BC8D8F38E716Q33938126-38BE4200-DAB8-44B1-BB7A-B6B7D4FA89EAQ33976270-8502791D-3DF2-4157-8EBD-0DCF98BA0541Q33983391-1B1BFD44-3B01-4F24-A030-F89B0513275FQ34230437-811FF2F9-6217-431C-BE9A-2EF4CCE3862AQ34252097-A3AD2E8E-5CA2-4AEC-84C0-8ADB13CC19C2Q34274586-BA592A14-BCAB-4BF1-9B29-6DF15E15F721Q34371891-EF94305E-41B9-447D-9815-ED7469CB01D3Q34421752-5CB52B86-FC75-4034-A7C0-51712A616A43Q34510522-F9F0E7AA-9B9A-4A03-ABE1-C71B3EF7719CQ34641507-3D09E3DF-EB2D-44DE-9BE6-FDD99512502BQ35014528-56B094E4-4596-42A6-ADBB-D8E6ADD785D7Q35113486-6F2BAC0D-AE86-4DC5-9E12-27DB90241820Q35122154-8A0D353C-8AF5-4172-940F-51B4F381219EQ35133558-160CB881-C452-4516-A397-1B5FA64629BBQ35135948-8A357485-0B45-4D1B-87F8-2825A2CC524FQ35254700-0A67865D-7EF9-4DA4-A931-FAE9BEB8F9C0Q35385242-009C412F-068F-40E4-AA19-4831CD374A99Q35536519-65116B5A-95B2-46FC-AEBE-8D61AB14D32EQ35562378-9702DB6A-2398-452B-AED9-2C4F7AEDFD03Q35573800-D6AB97F6-51C5-41A1-B16D-D51387CCF4DBQ35644656-17927A29-2B01-413E-9AC1-1071AB2C6365Q35646255-602DFC0E-E946-4B05-A326-601AC338B7B2Q35648571-5337BCF5-2842-4C5B-BA93-C82717364CACQ35648663-48B62032-F7ED-4A1B-86CC-78A9C7CF95DFQ35650768-97BABB5A-C11F-4BB2-B360-B9B68FB2F9A4Q35651669-6FEC94AD-F2D4-4264-823F-D07BE63A6B29
P2860
Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria
description
1982 nî lūn-bûn
@nan
1982 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@ast
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@en
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@nl
type
label
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@ast
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@en
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@nl
prefLabel
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@ast
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@en
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@nl
P2093
P2860
P356
P1476
Azthreonam (SQ 26,776), a synt ...... aerobic gram-negative bacteria
@en
P2093
Georgopapadakou NH
P2860
P356
10.1128/AAC.21.1.85
P407
P577
1982-01-01T00:00:00Z